August 19, 2021 7:37am

A “witching: option expiration on Friday

The Biostage (BSTG) Chronicles: The present and past keeps casting aspersions on the reputation and integrity of BSTG as stock pricing continues to tumble; did they forget that transparency has its virtues?

Pre-open indications: SELLs: 7; BUYs: 1 Maintain SELL: 1

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!

What I provide is a trusted source of share pricing intelligence

Dow futures are DOWN -0.88% (-306 points), S&P futures are DOWN -0.80% (-35 point) and NASDAQ futures are also DOWN -0.64% (-95 points)


U.S. stock futures were down and sinking lower on Thursday,

European markets sank as investors digested the latest Federal Reserve minutes,

Asia-Pacific markets fell with Chinese tech stocks slipping again as regulatory fears continue to weigh on investor sentiment.


Data Docket: Investors will monitor new jobless claims data due Thursday morning. Economists expect a total of 365,000 in the week ended Aug. 14, slightly below the total of 375,000 in the prior week.

  • About the Fed minutes: The central bank discussed starting to remove some of the monetary stimulus, likely before the end of the year as the U.S. economy gathers momentum; tapering would not necessarily mean an imminent rate increase.



Not looking good today …

Yesterday, the Dow stocks dropped 380 points, falling for a second day, while the S&P 500 slid 47 points and the Nasdaq dropped 130 points on Wednesday.


If you didn’t know what happen at last night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

  • Wednesday’s evening’s recap: “another early rout but, with no comeback in the cell and gene therapy sector” …
  • The Nasdaq closed DOWN -130.27 points (-0.89%)
  • The IBB closed down -1.39% and XBI closed down -1.69%
  • Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with very LOW volume of 1 of 24-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +3.36 points or +20.44% at 21.57
  • Wednesday’s percentage (%) of the 9-upside were +0.36% (BLCM) to +7.77% (FATE) while the 24-downside -0.16% (BLFS) to -7.60% (RARE);


  • August: 6 positive and 7 negative close
  • July: 6 positives, 1 holiday and 15 negative closes


  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes


  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday


Q2/21 Earnings releases …  … to date:


Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?

Biostage (BSTG) closed down -$0.10 with 739 shares traded after Tuesday’s flat with 1 share traded, Monday’s -$0.22 to $1.38 with 135 shares traded, Friday with 10 shares traded and last Thursday a with 50 shares traded.

The Bottom-Line Question: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND foe a year and a half with NO clinical trial initiative … so WHAT is the value proposition WHEN they’re BROKE?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.


Pre-open Indications: looking bleak …


Verastem (VSTM) closed down -$0.07 and has a positive +$0.05 or +1.923% aftermarket indication;



CRISPR Therapeutics (CTSP) closed down -$1.23 and has a negative -$2.61 or -2.19% pre-market indication,

Editas Medicine (EDIT) closed down -$1.12 and has a negative -$0.63 or -1.05% pre-market indication,

Fate Therapeutics (FATE) closed up +$6.56 and has a negative -$0.05 or -0.05% pre-market indication,

Global Blood therapeutics (GBT) closed down -$1.29 and has a negative -$0.28 or -1.06% pre-market indication,

Intellia Therapeutics (NTLA) closed down -$1.02 and has a negative -$0.43 or -0.28% pre-market indication;

Pluristem (PSTI) closed up +$0.09 and has a negative -$0.05 or -1.67% aftermarket indication;

Ultragenyx Pharmaceuticals (RARE) closed down -$6.74 and has a negative -$2.00 or -2.44% pre-market indication,


The BOTTOM LINE: When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

The alternating cycle of being oversold is the ability to be overbought after multiple sessions

Investors are worried that the clinical advances are in-short supply although 2024 seems to be the usual runway length and timing.

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)

Risk is no doubt increasing as we traverse through the month of August …

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is all but over … my advice, take a chance, roll the dice and then be ready to skim any new highs!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.